Filing summary
Registrant identity: The supplied filing is for CM Life Sciences, Inc., not GeneDx Holdings Corp. It describes a newly formed blank-check company (SPAC), not an operating diagnostics business. Verify that this is the intended filing before relying on these figures.
Business context and reporting period
This unaudited Form 10-Q covers the period from incorporation on July 10, 2020 through September 30, 2020; it does not provide a comparable prior-year period. CM Life Sciences completed its IPO on September 4, 2020 and was seeking a business combination. It reported no operating activity or revenue through quarter-end.
Financial condition and results
| Metric | Period-end or period amount |
|---|---|
| Revenue | None; no operating revenue had been generated. |
| General and administrative expenses | $59,713 |
| Trust-account interest income | $2,790 |
| Net loss | $56,923; Class B loss per share was $0.01. |
| Cash outside trust | $1,139,979 |
| Cash and marketable securities in trust | $442,752,790 |
| Total assets | $444,218,211 |
| Total liabilities | $15,540,597, including a $15,496,250 deferred underwriting fee payable upon a completed business combination. |
| Operating cash flow | $(365,808) |
| Investing cash flow | $(442,750,000), primarily the deposit into trust. |
| Financing cash flow | $444,255,787 |
There was no reported debt at September 30, 2020 and no off-balance-sheet financing arrangement. The 42,367,761 public Class A shares subject to redemption, valued at $423,677,610, were classified as temporary equity rather than stockholders’ equity. Stockholders’ equity was $5,000,004. Operating margins are not meaningful given the absence of revenue.
Material changes, outlook, and risks
- The company raised $442.75 million in its IPO and $10.855 million through private-placement warrants; it placed $442.75 million in trust. IPO and related transaction costs totaled $24.895 million.
- Management intended to use substantially all trust funds toward a business combination. The company could also issue additional securities or incur debt; up to $150 million of forward-purchase shares were contemplated, subject to investor and transaction conditions.
- The company had to complete a business combination by September 4, 2022 or redeem public shares and liquidate. Public-share redemptions could reduce available transaction funding; warrants would expire worthless if no combination were completed.
- Management said cash outside trust was expected to cover planned expenditures, but warned that actual search and transaction costs could exceed estimates and additional financing might be needed. No assurance of completing a business combination was given.
- Management stated that COVID-19 could adversely affect the company’s financial position, operations, or target search, but the specific impact was not determinable. Trust assets were invested in Treasury-related money-market funds; management reported no material market or interest-rate risk from their short-term nature.
- Management reported disclosure controls and procedures were effective and no material change in internal control over financial reporting. No legal proceedings or material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- Confirm the registrant: the filing names CM Life Sciences, Inc., not GeneDx Holdings Corp.
- Review the IPO prospectus and subsequent filings for the business-combination terms, redemption mechanics, and any later transaction or change in registrant.
- Verify trust-account balances, redemption levels, deferred underwriting fees, and whether the forward-purchase commitments became available or were reduced.
- Assess whether the company completed a business combination by the September 4, 2022 deadline and how that affected public shares and warrants.